Introduction {#s1}
============

The incidence of melanoma is increasing at one of the highest rates for any form of cancer in the United States [@pone.0000594-Jemal1]. At present, there are no systemic agents available that significantly extend the lifespan of patients with advanced disease, and the key to improved survival in all affected individuals remains early diagnosis and treatment. While early stage disease may result in occasional deaths, there are no available tests to predict which early stage tumors have a high likelihood of progression and therefore a worse prognosis. Thus, an urgent need exists for the identification of molecular signatures of melanoma progression which can be used to develop accurate prognostic markers and effective targeted therapies. High-throughput gene expression profiling technologies offer an opportunity to uncover critical molecular events in the development and progression of human melanoma and can be used to design improved prognostic testing and effective treatment strategies. Previous transcriptome analyses in other malignancies have provided valuable information for the assessment of patient group classifications such as subgroups of patients that are likely to respond to a particular therapy [@pone.0000594-Quackenbush1]. Expression profiling of metastatic melanomas was able to identify previously unrecognized subtypes of disease and predict phenotypic characteristics which may be of importance to melanoma progression [@pone.0000594-Bittner1]. Further studies using serial analysis of gene expression (SAGE) and cDNA arrays have yielded the identification of additional novel molecules and pathways which may be involved in melanoma development[@pone.0000594-Smith1]--[@pone.0000594-Hoek1]. Such studies have been limited in utility due to the lack of concordance from one study to the next suggesting tumor heterogeneity [@pone.0000594-Gyorffy1]. In addition, the limited availability of primary tissue from early stages of disease has hindered the ability to identify serial molecular events that lead to melanoma onset. This shortcoming of tissue availability has largely restricted gene expression profiling studies in melanoma to the use of small numbers of established tumor cell lines and cases of metastatic disease.

Previous studies of primary human melanomas have identified gene signatures associated with tumor progression [@pone.0000594-Haqq1]--[@pone.0000594-Jaeger1]. These signatures included upregulation of cell cycle regulatory proteins, mitotic checkpoint genes, genes involved in DNA replication and repair, and cellular stress response genes in addition to loss of genes promoting apoptosis; however, few of the genes identified in these studies were concordant suggesting limitations due to tumor variability. Since better knowledge of gene expression signatures associated with melanoma progression may identify improved screening tools and therapeutic strategies, we used high density cDNA microarrays for gene expression profiling of genetically well-defined melanoma cell lines isolated from distinctive stages of tumor progression. Novel data reduction algorithms were used to identify gene signatures associated with tumor invasion and metastasis. Here we report unique sets of gene expression signatures that are associated with melanoma progression. Many of these pathways have previously been implicated in melanoma progression; however, the specific signature genes identified are novel. These particular progression-associated genes may reflect the underlying molecular mechanisms of the various phases in the known tumor progression pathways of melanoma. As such, the pathways and molecules identified in this study have the potential to be utilized as therapeutic targets for melanoma as well as novel molecular markers for melanoma progression. Moreover, these studies support the use of renewable sources of tumor cells, such as informative tumor cell lines, for the early identification of genes associated with malignant progression which can be subsequently validated using more precious primary tissue specimens.

Results {#s2}
=======

In order to define gene expression patterns during the course of melanoma development and progression, we evaluated a series of primary and metastatic melanoma cells derived from lesions of discrete phases of melanoma progression as well as pools of primary human melanocytes. Tumor cell lines derived from three radial growth phase (RGP) melanomas (WM35, SBC12, and WM1552C), four vertical growth phase (VGP) melanomas (WM902B, WM278, WM983A, and WM793), and three metastatic melanomas (WM852, WM983B, 1205Lu) were evaluated. These cell lines possess a notable ability to recapitulate the clinical stages of disease from which they were derived [@pone.0000594-HsuMY1], [@pone.0000594-Satyamoorthy1] and have been characterized with respect to tumorigenicity and metastasis [@pone.0000594-Meier1]--[@pone.0000594-ValyiNagy1]; cellular growth characteristics including life span, growth factor dependency, anchorage-independent growth [@pone.0000594-HsuMY1]; and pigmentation and morphology [@pone.0000594-Herlyn2]. In addition, cytogenetic analyses in these cell lines including non-random abnormalities such as deletions, translocations, and amplifications have been well-documented and suggest high relevance to the primary tumor of origin (reviewed in [@pone.0000594-HsuMY1]).

Global gene expression patterns were obtained using Affymetrix gene chips and comparison of gene expression profiles was performed using hierarchical clustering analysis. This clustering analysis identified two distinct groups of melanoma cell lines based on the similarity of their expression patterns, separating radial growth phase (RGP) and metastatic melanomas (MM) ([Figure 1](#pone-0000594-g001){ref-type="fig"}); however, vertical growth phase (VGP) melanomas failed to form a distinctive cluster ([Figure 1A](#pone-0000594-g001){ref-type="fig"}). The first group, which we characterized as "less-aggressive" primary melanomas (designated as Group1), included all three RGP melanomas (WM35, Sbcl2, and WM1552C) and two VGP melanomas (WM902B and WM278). The second group, which we characterized as "more-aggressive" melanomas (designated as Group2), included all three metastatic melanomas (WM853, WM983B, and 1205Lu) and two VGP melanomas (WM983B and WM793). Additional cluster analyses with different linkage matrices produced similar results (data not shown). Of note, only 2 of the 10 cell lines (Sbcl2 and WM853) were found to be wildtype for BRAF kinase and this genotype failed to demonstrate a notable cluster in our hierarchical analyses.

![Evaluation of gene expression profiles from melanoma cells lines of varying stages of progression identifies a signature for aggressive melanomas.\
A) Unsupervised hierarchical clustering of melanoma cells indicates the existence of two distinct groups of melanoma cells based on global gene expression patterns (Group 1: RGP2, RGP3, RGP1, VGP1, and VGP2; Group 2: VGP3, MM2, MM1, VGP4, and MM3). B) SAM plot sheet illustrating a signature for differentially expressed genes in aggressive melanomas. Gene expression profiles from the two groups of melanomas were compared (Group1 vs. Group 2) and a differentially expressed gene signature was identified by SAM. Red and green dots represent gene probesets upregulated and downregulated respectively in Group 2. C) The melanoma gene signature was visualized using Java TreeView. Genes over four-fold differentially expressed are indicated on the right side of the image. D) Validation of select differentially expressed genes by real-time RT-PCR. Three genes upregulated in aggressive melanomas (Group 2) were selected for analysis and their differential expression was verified. 3.0 µg of total RNA was subjected to cDNA synthesis reaction as described in the [materials and methods](#s4){ref-type="sec"}. 1.0 µl of the final cDNA samples (100 µl) were used for real-time Q-PCR reaction. For the measurement of gene transcript level, standard curves were generated for each gene using known amount of PCR amplified product from the corresponding genes. Error bars are SD of three independent experiments.](pone.0000594.g001){#pone-0000594-g001}

In order to identify a cohort of genes differentially expressed between our defined groups of melanomas, the gene expression array dataset was subjected to the microarray data analysis program Significance Analysis of Microarray (SAM) [@pone.0000594-Tusher1]. This analysis resulted in 142 differentially expressed probesets with a 3.5 % false discovery rate ([Figure 1B and C](#pone-0000594-g001){ref-type="fig"}). In total, 89 probe sets representing 65 well-defined genes were found to be upregulated in more-aggressive (group 2) versus less-aggressive (group 1) melanomas and 53 probe sets representing 37 well-defined genes were found to be downregulated ([Table S1](#pone.0000594.s003){ref-type="supplementary-material"}). When more stringent criteria were applied (well-characterized genes which are differentially expressed greater than 4-fold) to this signature, we identified 21 upregulated and 5 downregulated genes in the more-aggressive melanoma cells ([Figure 1C](#pone-0000594-g001){ref-type="fig"}). Of note, the set of genes highly expressed in more-aggressive melanomas includes many novel genes with reported functional roles in cell cycle regulation and proliferation such as *ZWINT, CDCA2, NCAPH, NCAPG, NCAPG2, PBK, NUSAP1, BIRC5, ESCO2, HELLS, MELK, and CDKN2C* [@pone.0000594-Obuse1]--[@pone.0000594-Zindy1] as well as genes that are involved DNA replication and repair processes including *GINS1, GINS4, RAD54L, TYMS*, and *DHFR* [@pone.0000594-Ueno1]--[@pone.0000594-Banerjee1] ([Table 1](#pone-0000594-t001){ref-type="table"}). Differential expression of these genes was validated by quantitative real-time RT-PCR ([Figure 1D](#pone-0000594-g001){ref-type="fig"}).

10.1371/journal.pone.0000594.t001

###### Genes with altered expression in aggressive melanoma cells are involved in cell cycle control, cell proliferation, DNA repair and replication[a](#nt101){ref-type="table-fn"}.

![](pone.0000594.t001){#pone-0000594-t001-1}

  Probe Set ID                     Gene Title                                Gene Symbol                Fold [b](#nt102){ref-type="table-fn"}                  Function
  --------------- -------------------------------------------- --------------------------------------- --------------------------------------- -----------------------------------------
  227350_at               Helicase, lymphoid-specific           HELLS[c](#nt103){ref-type="table-fn"}                    8.5                              cell proliferation
  202589_at                  thymidylate synthetase                             TYMS                                     7.2                          DNA replication, DNA repair
  204558_at                RAD54-like (S. cerevisiae)                          RAD54L                                    6.2                      DNA repair, response to DNA damage
  204825_at         maternal embryonic leucine zipper kinase                    MELK                                     5.9                       Mitosis, protein phosphorylation
  204159_at        cyclin-dependent kinase inhibitor 2C (p18)                  CDKN2C                                    5.8                                  cell cycle
  212949_at              barren homolog 1 (Drosophila)                          NCAPH                                    5.8                      cell cycle, chromosome condensation
  219588_s\_at              leucine zipper protein 5                           NCAPG2                                    4.6                      cell cycle, chromosome condensation
  218663_at            chromosome condensation protein G                       HCAPG1                                    4.5                      cell cycle, chromosome condensation
  211767_at          GINS complex subunit 4 (Sld5 homolog)                      GINS4                                    5.6                      DNA replication, cell proliferation
  206102_at          GINS complex subunit 1 (Psf1 homolog)                      GINS1                                    4.7                      DNA replication, cell proliferation
  202095_s\_at        baculoviral IAP repeat-containing 5                       BIRC5                                    5.1                          G2/M transition cell cycle
  219148_at                    PDZ binding kinase                                PBK                                     5.1                       mitosis, protein phosphorylation
  235178_x\_at       establishment of cohesion 1 homolog 2                      ESCO2                                    5.1                                  cell cycle
  226661_at             cell division cycle associated 2        CDCA2[c](#nt103){ref-type="table-fn"}                    4.9                                  cell cycle
  204026_s\_at                  ZW10 interactor                                 ZWINT                                    4.7                       cell cycle, spindle organization
  202534_x\_at              dihydrofolate reductase                             DHFR                                     4.5                    DNA replication, nucleotide metab olism
  218039_at        nucleolar and spindle associated protein 1                  NUSAP1                                    4.1                      cell cycle, chromosome condensation
  1555788_a\_at         tribbles homolog 3 (Drosophila)         TRIB3[c](#nt103){ref-type="table-fn"}                   −6.7                         anti-proliferation, apoptosis

Genes with greater than four-fold differential expression are shown.

Fold represents average expression ratio of group 2 over Group1.

Genes with multiple probesets are shown with data from a single representative probeset.

Since we were interested in defining melanoma progression signatures, and all melanomas are initiated in primary human melanocytes, we evaluated our expression profiling data in the context of cultured neonatal primary human melanocytes ([Figure 2](#pone-0000594-g002){ref-type="fig"}). Surprisingly, when two pools of short-term cultured primary human melanocytes (HPM1 and HPM2) were included in the previously employed hierarchical clustering protocol, the global gene expression pattern of the normal melanocytes was found to be more similar to that of the more-aggressive melanomas (Group 2) than the less-aggressive melanomas (Group 1) ([Figure 2A](#pone-0000594-g002){ref-type="fig"}). Since early cultures of primary human melanocytes derived from neonatal foreskins divide rapidly yet possess a normal differentiation program, we reasoned that the similarities of these cells to more aggressive tumors was likely due to their proliferative potential. In order to test this hypothesis we compared gene expression profiles of more-aggressive melanoma cells (Group 2) to those of short-term cultured primary human melanocytes. Expression profiles were subjected to SAM analysis which identified a cohort of differentially expressed genes with a 0.85% false discovery rate. Remarkably, all differentially expressed genes were found to be down-regulated genes in aggressive melanoma cells versus primary human melanocytes suggesting that loss of specific gene signatures may be a key event in the development of advanced melanomas ([Figure 2B](#pone-0000594-g002){ref-type="fig"}). Further assessment of all melanoma expression profiles using TreeView revealed that the majority of these melanoma-associated genes are also down-regulated in the less-aggressive primary melanomas (Group1) ([Figure 2C](#pone-0000594-g002){ref-type="fig"}). This gene signature is comprised of critical mediators of cellular adhesion and melanocyte development and differentiation and includes: *CDH3, CDH1, c-KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R,* and *OCA2* [@pone.0000594-Nishimura1]--[@pone.0000594-Suzuki1] ([Table 2](#pone-0000594-t002){ref-type="table"}). While such a loss of cellular adhesion by E-cadherin and P-cadherin has been extensively documented in melanoma (reviewed in [@pone.0000594-Bonitsis1]), and the loss of differentiation-associated genes is not wholly surprising, this signature does notably identify specific defects in the intrinsic melanocyte development program that may contribute to melanoma development. In addition, genes with tumor suppressor and metastasis suppressor functions (DPP4, SYK) are included in this melanoma signature [@pone.0000594-Wesley1], [@pone.0000594-Coopman1]. Significant down-regulation of these genes in the aggressive metastatic melanoma cells was validated using semi-quantitative duplex RT-PCR ([Figure 2D](#pone-0000594-g002){ref-type="fig"}). Furthermore, this differentially expressed "melanoma signature" contains many genes whose functional roles in melanoma progression have not been well characterized and may provide novel insights into the early development of melanoma from primary melanocytes.

![Evaluation of differential gene expression from aggressive melanomas (Group 2) vs. primary human melanocytes identifies a signature characterized by loss of differentiation-associated genes.\
A) Java TreeView analysis of melanoma cell lines and primary human melanocytes clusters two pools of human primary melanocytes (HPM1 and HPM2) with the Group 2 melanomas. B) SAM plot sheet illustrating a signature of down-regulated genes in group 2 melanomas compared to HPMs. Gene expression profiles of two pools of human primary melanocytes (HPM1 and HPM2) were compared to those of aggressive melanomas (Group 2) and a differentially expressed gene signature was identified by SAM. C) The melanoma gene signature was visualized using Java TreeView. Genes over five-fold downregulated are indicated on the right. D) Validation of differential expression for selected genes by semi-quantitative duplex RT-PCR. Four genes (CDH3, KIT, DPP4, SYK) downregulated in the aggressive melanoma cells (Group 2) were selected for analysis and their differential expression was verified.](pone.0000594.g002){#pone-0000594-g002}

10.1371/journal.pone.0000594.t002

###### Differential expression of genes that are downregulated in aggressive melanoma cells (Group2) compared to primary human melanocytes. Genes with greater than five-fold differential expression are shown [a](#nt104){ref-type="table-fn"}.

![](pone.0000594.t002){#pone-0000594-t002-2}

  Probe Set ID                        Gene Title                                    Gene Symbol                 Fold [b](#nt105){ref-type="table-fn"}              Function
  --------------- -------------------------------------------------- ----------------------------------------- --------------------------------------- ---------------------------------
  203256_at           cadherin 3, type 1, P-cadherin (placental)                       CDH3                                    −161.9                            cell adhesion
  201131_s\_at       cadherin 1, type 1, E-cadherin (epithelial)       CDH1[c](#nt106){ref-type="table-fn"}                     −35.1                            cell adhesion
  205051_s\_at               v-kit viral oncogenehomolog                                KIT                                     −94.0                         signal transduction
  1565162_s\_at         microsomal glutathione S-transferase 1         MGST1[c](#nt106){ref-type="table-fn"}                    −92.5                                 ---
  203716_s\_at              dipeptidyl-peptidase 4 (CD26)              DPP4[c](#nt106){ref-type="table-fn"}                     −74.0                             proteolysis
  206039_at               RAB33A, member RAS oncogene family                          RAB33A                                    −70.4                         signal transduction
  226311_at                   CDNA clone IMAGE: 30924414                                ---                                     −64.3                                 ---
  236901_at                     ADAM metallopeptidase                                 ADAMTS2                                   −62.1                             proteolysis
  229095_s\_at                      similar to LIM                                   LOC440895                                  −54.6                                 ---
  227705_at         transcription elongation factor A (SII)-like 7                    TCEAL7                                    −49.1                                 ---
  1556698_a\_at             hypothetical protein LOC285513                           LOC285513                                  −35.0                                 ---
  213924_at                    metallophosphoesterase 1                                MPPE1                                    −33.5                                 ---
  209569_x\_at               DNA segment on chromosome 4              D4S234E[c](#nt106){ref-type="table-fn"}                   −31.6                     dopamine receptor signaling
  202283_at         serpin peptidase inhibitor, clade F, member 1                    SERPINF1                                   −29.2                      development/proliferation
  204570_at        cytochrome c oxidase subunit VIIa polypeptide 1                    COX7A1                                    −28.8                         electron transport
  202546_at             vesicle-associated membrane protein 8                          VAMP8                                    −27.9                     vesicle-mediated transport
  208017_s\_at      MCF.2 cell line derived transforming sequence      MCF2[c](#nt106){ref-type="table-fn"}                     −27.8                   intracellular signaling cascade
  217248_s\_at            solute carrier family 7, member 8           SLC7A8[c](#nt106){ref-type="table-fn"}                    −27.1                        amino acid transport
  206479_at          transient receptor potential cation channel                       TRPM1                                    −25.8                          cation transport
  205114_s\_at              chemokine (C-C motif) ligand 3                             CCL3                                     −25.6                       chemotaxis/inflammatory
  220813_at                cysteinyl leukotriene receptor 2                           CYSLTR2                                   −25.3                         signal transduction
  206355_at        G protein, alpha activating activity polypeptide    GNAL[c](#nt106){ref-type="table-fn"}                     −23.5                         signal transduction
  237472_at              SRY (sex determining region Y)-box 1                          SOX1                                     −23.4                     regulation of transcription
  203815_at               glutathione S-transferase theta 1                            GSTT1                                    −22.1                         response to stress
  212599_at               autism susceptibility candidate 2                            AUTS2                                    −20.3                                 ---
  206426_at                            melan-A                                         MLANA                                    −20.3                                 ---
  225407_at                      myelin basic protein                   MBP[c](#nt106){ref-type="table-fn"}                     −19.7                           CNS development
  219436_s\_at                        endomucin                                        EMCN                                     −19.4                                 ---
  1556427_s\_at            similar to hypothetical protein                           LOC221091                                  −17.9                                 ---
  201425_at        aldehyde dehydrogenase 2 family (mitochondrial)                     ALDH2                                    −17.8                       carbohydrate metabolism
  207144_s\_at          Cbp/p300-interacting transactivator 1                         CITED1                                    −17.7                     regulation of transcription
  212338_at                           myosin ID                                        MYO1D                                    −17.7                                 ---
  219315_s\_at           chromosome 16 open reading frame 30                         C16orf30                                   −17.0                                 ---
  227532_at               leucine rich repeat containing 39                           LRRC39                                    −16.5                                 ---
  206569_at                         interleukin 24                                     IL24                                     −16.1                      apoptosis/immune response
  226068_at                     spleen tyrosine kinase                  SYK[c](#nt106){ref-type="table-fn"}                     −15.9                         signal transduction
  213122_at                          TSPY-like 5                                      TSPYL5                                    −15.8                         nucleosome assembly
  204187_at               guanosine monophosphate reductase                            GMPR                                     −14.7                       nucleic acid metabolism
  204880_at            O-6-methylguanine-DNA methyltransferase                         MGMT                                     −14.3                             DNA repair
  204777_s\_at           mal, T-cell differentiation protein                            MAL                                     −14.2                        cell differentiation
  1555505_a\_at        tyrosinase (oculocutaneous albinism IA)                          TYR                                     −13.6                        melanin biosynthesis
  226778_at               chromosome 8 open reading frame 42          C8orf42[c](#nt106){ref-type="table-fn"}                   −13.1                                 ---
  225792_at                  hook homolog 1 (Drosophila)                               HOOK1                                    −12.5                      cytoskeleton organization
  209924_at                chemokine (C-C motif) ligand 18                             CCL18                                    −11.8                       chemotaxis/inflammatory
  211427_s\_at          potassium inwardly-rectifying channel,                        KCNJ13                                    −11.7                            ion transport
  213556_at                      similar to R28379-1                                 LOC390940                                  −11.7                                 ---
  240173_at                       transcribed locus                                     ---                                     −11.5                                 ---
  206498_at                   oculocutaneous albinism II                               OCA2                                     −11.4                      eye pigment biosynthesis
  241600_at                       transcribed locus                                     ---                                     −11.0                                 ---
  205297_s\_at        CD79b molecule, immunoglobulin-associated                        CD79B                                    −10.9                           immune response
  228256_s\_at      erythrocyte membrane protein band 4.1 like 4A                    EPB41L4A                                   −10.9                                 ---
  223693_s\_at              hypothetical protein FLJ10324                            FLJ10324                                   −10.3                         signal transduction
  243727_at                          copine VIII                                       CPNE8                                    −10.1                                 ---
  232687_at             CDNA FLJ33091 fis, clone TRACH2000660                           ---                                     −9.9                                  ---
  232443_at            hypothetical gene supported by AF131741                       LOC441052                                  −9.9                                  ---
  236377_at                   transmembrane protein 132D                             TMEM132D                                   −9.1                                  ---
  211748_x\_at         prostaglandin D2 synthase 21kDa (brain)                         PTGDS                                    −9.0                          lipid biosynthesis
  204112_s\_at              histamine N-methyltransferase                              HNMT                                     −8.7                     respiratory gaseous exchange
  228057_at             DNA-damage-inducible transcript 4-like                        DDIT4L                                    −8.6                                  ---
  51158_at                        hypothetical gene                                  LOC400451                                  −8.3                                  ---
  209550_at                     necdin homolog (mouse)                                  NDN                                     −8.3                       regulation of cell cycle
  214255_at                   ATPase, Class V, type 10A                               ATP10A                                    −7.9                           cation transport
  1553485_at                hypothetical protein LOC151278                           FLJ32447                                   −7.8                                  ---
  204273_at                   endothelin receptor type B                               EDNRB                                    −7.6                          G-protein signaling
  235758_at                 paraneoplastic antigen like 6A                            PNMA6A                                    −7.6                                  ---
  213816_s\_at                    met proto-oncogene                                    MET                                     −7.2                          cell proliferation
  227704_at              full-length cDNA clone CS0CAP008YI07                           ---                                     −7.1                                  ---
  224566_at               trophoblast-derived noncoding RNA                           TncRNA                                    −6.9                                  ---
  207610_s\_at          EGF-like module containing, mucin-like                         EMR2                                     −6.8                          signal transduction
  232504_at                 hypothetical protein LOC285628                           LOC285628                                  −6.8                                  ---
  241966_at            myosin VA (heavy polypeptide 12, myoxin)        MYO5A[c](#nt106){ref-type="table-fn"}                    −6.7                         actin-based movement
  229925_at               solute carrier family 6, member 17                          SLC6A17                                   −6.6                      neurotransmitter transport
  229251_s\_at                two pore segment channel 2               TPCN2[c](#nt106){ref-type="table-fn"}                    −6.2                           cation transport
  216059_at           paired box gene 3 (Waardenburg syndrome 1)       PAX3[c](#nt106){ref-type="table-fn"}                     −6.2                              development
  227949_at               phosphatase and actin regulator 3                           PHACTR3                                   −5.7                                  ---
  209685_s\_at                 protein kinase C, beta 1                               PRKCB1                                    −5.6                    intracellular signaling cascade
  204995_at        cyclin-dependent kinase 5, regulatory subunit 1                    CDK5R1                                    −5.3                        neuron differentiation
  206020_at               suppressor of cytokine signaling 6                           SOCS6                                    −5.0                       regulation of cell growth
  221036_s\_at          anterior pharynx defective 1 homolog B                         APH1B                                    −5.0                        Notch signaling pathway
  205458_at                    melanocortin 1 receptor                                 MC1R                                     −5.0                          G-protein signaling

Genes with greater than five-fold differential expression are shown.

Fold represents average expression ratio of aggressive metastatic melanoma samples (group2) over normal primary human melanocyte samples.

Gene with multiple probesets are shown with a representative probeset.

A current melanoma progression model suggests the sequential evolution of primary *in situ* tumors and minimally invasive tumors which are termed "radial growth phase", followed by a subsequent conversion to a more aggressive "vertical growth phase", in which tumor cells are programmed to cross the epidermal basement membrane and invade vertically into the dermis. It has been postulated that the VGP is the critical stage in which a tumor gains metastatic capacity. We therefore compared the gene expression profiles of RGP and VGP melanomas using a uniquely designed data reduction algorithm in order to identify genes that are likely to be relevant to this critical invasive phenotype ([Figure 3A](#pone-0000594-g003){ref-type="fig"}). Our melanoma invasion-specific signature is notably characterized by the inclusion of several genes involved in chemotaxis and the inflammatory response (*CXCL1, CXCL2, IL8,* and *IL6*), cell adhesion (*HNT, ITGA4, ITGB8, CSPG2, ZP4,* and *FLRT3*), and extracellular matrix organization (*MMP1, COL4A1, COL4A2,* and *COL5A2*) ([Table 3](#pone-0000594-t003){ref-type="table"}). These genes and their relative expression profiles are depicted in [Figure 3B](#pone-0000594-g003){ref-type="fig"}. These cellular processes have previously been implicated in tumor progression for a wide variety of malignancies including melanoma and are felt to be essential components of tumor invasion and metastasis. In addition, many of these invasion-specific signature genes are also upregulated in metastatic melanomas ([Figure 3B](#pone-0000594-g003){ref-type="fig"}). The differential expressions were validated on the selected genes using semi-quantitative duplex-PCR analysis ([Figure 3C](#pone-0000594-g003){ref-type="fig"}).

![Identification of an invasion-specific gene signature for melanoma.\
A) The three-step data reduction algorithm used for identification of a melanoma invasion-specific signature. (see detailed description in Data Extraction and Statistical Analysis section of [Methods](#s4){ref-type="sec"}). B) Relative expression levels of melanoma invasion-specific signature genes in all cells analyzed including human primary melanocytes (HPM1, HPM2). C) Validation of differential expression for selected genes by semi-quantitative duplex RT-PCR. Four genes (IL-8, IGFBP3, CXCL1, CXCL2) that are upregulated in invasive melanomas were selected and their differential expression was verified. D) Promoter analysis of selected genes from the melanoma invasion-specific signature identifies putative NF-κB binding *cis* elements. E) Immunofluorescence staining of NF-κB in invasive (WM902B) vs. non-invasive (WM1552C) melanoma cells demonstrates constitutive activation and nuclear trafficking of NF-κB in invasive melanomas.](pone.0000594.g003){#pone-0000594-g003}

10.1371/journal.pone.0000594.t003

###### Melanoma invasion-specific signature genes that are upregulated in VGP compared to RGP melanoma cells [a](#nt107){ref-type="table-fn"}.

![](pone.0000594.t003){#pone-0000594-t003-3}

  Probe Set ID                                 Gene Title                                              Gene Symbol                  Fold [b](#nt108){ref-type="table-fn"}        Biological Process
  --------------- --------------------------------------------------------------------- ------------------------------------------ --------------------------------------- ------------------------------
  204470_at                         chemokine (C-X-C motif) ligand 1                                      CXCL1                                     62.3                      chemotaxis/inflammatory
  1555471_a\_at                                 formin 2                                                   FMN2                                     38.8                            development
  204475_at                             matrix metallopeptidase 1                                          MMP1                                     34.2                    proteolysis/ECM organization
  202196_s\_at                     dickkopf homolog 3 (Xenopus laevis)                     DKK3[c](#nt109){ref-type="table-fn"}                     24.5                       Wnt receptor signaling
  208894_at                  major histocompatibility complex, class II, DRα                             HLA-DRA                                    21.6                          immune response
  211506_s\_at                                interleukin 8                                IL8[c](#nt109){ref-type="table-fn"}                      19.9                      chemotaxis/inflammatory
  212730_at                                     desmuslin                                                  DMN                                      17.6                                ---
  210095_s\_at                insulin-like growth factor binding protein 3                IGFBP3[c](#nt109){ref-type="table-fn"}                    17.5                     regulation of cell growth
  206640_x\_at                                 G antigens                                                 GAGEs                                     15.5                     cellular defense response
  227566_at                                    neurotrimin                                                 HNT                                      15.2                           cell adhesion
  212327_at        hypothetical protein DKFZP686A01247[c](#nt109){ref-type="table-fn"}                     ---                                      14.8                        actomyosin structure
  211776_s\_at                erythrocyte membrane protein band 4.1-like 3                               EPB41L3                                    13.3                     cytoskeleton organization
  221729_at                             collagen, type V, alpha 2                                         COL5A2                                    12.7                          ECM organization
  226189_at                                 integrin, beta 8                                              ITGB8                                     12.4                        cell-matrix adhesion
  226847_at                                    follistatin                                 FST[c](#nt109){ref-type="table-fn"}                      11.4                            development
  222450_at                   transmembrane, prostate androgen induced RNA                TMEPAI[c](#nt109){ref-type="table-fn"}                    11.3                    androgen receptor signaling
  212942_s\_at                                  KIAA1199                                                 KIAA1199                                   11.2                    sensory perception of sound
  205207_at                        interleukin 6 (interferon, beta 2)                                      IL6                                      11.0                    immune response/inflammatory
  209619_at                  CD74 molecule, major histocompatibility complex                               CD74                                     10.7                          immune response
  211571_s\_at                chondroitin sulfate proteoglycan 2 (versican)               CSPG2[c](#nt109){ref-type="table-fn"}                     10.3                     cell adhesion/development
  223614_at                        chromosome 8 open reading frame 57                                    C8orf57                                    10.3                                ---
  207030_s\_at                     cysteine and glycine-rich protein 2                    CSRP2[c](#nt109){ref-type="table-fn"}                     10.0                         muscle development
  229800_at                        Doublecortin and CaM kinase-like 1                                    DCAMKL1                                    10.0                     nervous system development
  211538_s\_at                         heat shock 70kDa protein 2                                         HSPA2                                      9.9                          protein folding
  223638_at                     neuroblastoma breakpoint family, member 3                                 NBPF3                                      9.9                                ---
  209312_x\_at              major histocompatibility complex, class II, DR β1            HLA-DRB1[c](#nt109){ref-type="table-fn"}                    9.6                          immune response
  1561691_at                         hypothetical protein LOC285735                                     LOC285735                                    9.0                                ---
  209774_x\_at                      chemokine (C-X-C motif) ligand 2                                      CXCL2                                      8.6                      chemotaxis/inflammatory
  209392_at                        pyrophosphatase/phosphodiesterase 2                    ENPP2[c](#nt109){ref-type="table-fn"}                      8.3                      cell motility/chemotaxis
  231756_at                           zona pellucida glycoprotein 4                                        ZP4                                       7.8                    fertilization/cell adhesion
  209309_at                           alpha-2-glycoprotein 1, zinc                                        AZGP1                                      7.7                           cell adhesion
  241803_s\_at                                     ---                                                     ---                                       7.4                                ---
  204469_at                  protein tyrosine phosphatase, receptor-type, Z                               PTPRZ1                                     7.2                     nervous system development
  205885_s\_at                              integrin, alpha 4                                             ITGA4                                      7.2                           cell adhesions
  228293_at                              DEP domain containing 7                                          DEPDC7                                     7.0                    regulation of transcription
  213075_at                               olfactomedin-like 2A                                           OLFML2A                                     7.0                                ---
  219230_at                             transmembrane protein 100                                        TMEM100                                     7.0                                ---
  204681_s\_at                  Rap guanine nucleotide exchange factor 5                                 RAPGEF5                                     6.6                        signal transduction
  211980_at                            collagen, type IV, alpha 1                                         COL4A1                                     6.4                          ECM organization
  211991_s\_at              major histocompatibility complex, class II, DP α1                            HLA-DPA1                                    6.3                          immune response
  216959_x\_at                       neuronal cell adhesion molecule                                      NRCAM                                      6.3                        neuron cell adhesion
  209967_s\_at                      cAMP responsive element modulator                                      CREM                                      6.2                        signal transduction
  222162_s\_at                            ADAM metallopeptidase                                          ADAMTS1                                     6.1                            proteolysis
  233903_s\_at                Src domain-containing guanine exchange factor                SGEF[c](#nt109){ref-type="table-fn"}                      6.1                       Rho protein signaling
  207034_s\_at                       GLI-Kruppel family member GLI2                                        GLI2                                      6.1                           morphogenesis
  222853_at                 fibronectin leucine rich transmembrane protein 3                              FLRT3                                      6.1                           cell adhesion
  226436_at                   Ras association (RalGDS/AF-6) domain family 4                               RASSF4                                     6.0                        signal transduction
  219872_at                        chromosome 4 open reading frame 18                                    C4orf18                                     5.9                                ---
  211966_at                            collagen, type IV, alpha 2                                         COL4A2                                     5.8                          ECM organization
  209859_at                           tripartite motif-containing 9                                       TRIM9                                      5.8                                ---
  214023_x\_at                              tubulin, beta 2B                                              TUBB2B                                     5.7                     microtubule-based movement
  204702_s\_at                 nuclear factor (erythroid-derived 2)-like 3                                NFE2L3                                     5.7                    regulation of transcription
  205599_at                         TNF receptor-associated factor 1                                      TRAF1                                      5.6                        signal transduction
  212325_at                       hypothetical protein, DKFZP686A01247                                     ---                                       5.6                      actomyosin organization
  1554474_a\_at                         monooxygenase, DBH-like 1                                         MOXD1                                      5.6                      catecholamine metabolism
  235116_at                         TNF receptor-associated factor 1                                      TRAF1                                      5.2                        signal transduction
  210139_s\_at                        peripheral myelin protein 22                                        PMP22                                      5.1                     peripheral nervous develop
  203680_at                   protein kinase, cAMP-dependent, type II, beta                              PRKAR2B                                     5.0                        signal transduction

Genes with greater than five-fold upregulation are shown.

Fold represents average expression ratio of VGP melanoma cells over RGP melanoma cells.

Gene with multiple probesets are shown with a representative probeset.

Since the melanoma invasion-specific signature was associated with common functions of matrix invasion/inflammation/cell migration we sought to determine whether a common upstream regulatory pathway might link these signature genes. The eight most highly up-regulated genes from our melanoma invasion-specific signature were selected for further evaluation and gene promoter sequences were analyzed to identify transcription factor binding *cis* elements. This promoter analysis yielded a profile of transcription factors with common sequence elements in the signature genes. The most ubiquitous *cis* elements among the gene promoters evaluated were E12, E47, GCN4, GR, HES-1, IL-6, MEF-2, NF-κB, N-Oct-3, PU.1, RAR-alpha1, SRF, and the basal gene transcriptional complex components of TFIID, TBP, and TBF1. We notably identified the NF-κB binding sequence in 7 out of 8 of the most upregulated invasion-specific signature genes ([Figure 3D](#pone-0000594-g003){ref-type="fig"}). We were particularly interested in the NF-κB pathway as a mediator of melanoma invasion since our most highly upregulated invasion-specific genes, *CXCL-1* and *IL-8*, have previously been reported to be activated by NF-κB and had previously been implicated in melanoma progression (reviewed in [@pone.0000594-Ueda1]). Given the consequences of NF-κB activation in a cell, NF-κB function is highly regulated by specific cytosolic inhibitory activities which prevent inappropriate NF-κB activation and shuttling to the nucleus. Thus, only nuclear NF-κB is considered to be functionally activated. In order to evaluate NF-κB function in our tumor cell lines, we used NF-κB cellular localization as a surrogate marker for NF-κB activity. We find that invasive (VGP) melanomas posses both cytosolic (inactive) and nuclear (active) localization of NF-κB, while non-invasive (RGP) melanomas possess NF-κB confined to the cytosolic compartment suggesting specific activation of NF-κB during melanoma progression ([Figure 3E](#pone-0000594-g003){ref-type="fig"}).

Discussion {#s3}
==========

Molecular profiling studies of melanoma to date have been variably successful and often inconsistent. Much of this inconsistency has been attributed to the heterogeneous nature of this malignancy and the lack of significant sources of meaningful archived tissue specimens for analysis. In addition, variable sample preparation techniques are also likely to lead to disparate results between investigators. Here we have used a series of well-defined melanoma cell lines from varying stages of malignant progression to assess molecular signatures associated with disease progression. These cell lines have undergone extensive characterization of their tumorigenic potential and invasion capacity [@pone.0000594-Meier1], [@pone.0000594-Hsu1], and have been shown to possess a remarkable ability to recapitulate the clinical stages of disease from which they were derived. We show that unsupervised hierarchical clustering of global gene expression profiles of melanoma cell lines allows for the classification of tumor cells into 2 groups ([Figure 1A](#pone-0000594-g001){ref-type="fig"}) that we have defined as less-aggressive (Group 1) and more-aggressive (Group 2) melanomas. While all radial growth phase melanomas clustered in Group 1, and all metastatic melanomas clustered in Group 2, vertical growth phase melanomas failed to form a distinctive cluster suggesting that vertical growth phase melanomas may be considered to be a transient or transition phase within the current melanoma progression model [@pone.0000594-Clark1]. Aggressive (Group 2) melanomas were characterized by upregulation of genes associated with cell cycle progression, DNA replication and repair, and altered expression of apoptosis-related genes including upregulation of the antiapoptotic gene BIRC5/survivin [@pone.0000594-Grossman1] and downregulation of the novel stress-associated apoptosis inducer TRIB3 [@pone.0000594-Ohoka1] ([Table 1](#pone-0000594-t001){ref-type="table"}). These signature genes for melanoma progression are remarkably similar to those obtained from recent large-scale studies using primary human melanomas and suggest high correlation with alterations seen in primary tumor specimens [@pone.0000594-Winnepenninckx1]. Notably, we did not identify a dominant signature associated with BRAF kinase mutations which may be reflective of the relative infrequency of wildtype BRAF in these cell lines. As a whole, this gene signature suggests a series of molecular alterations occur in aggressive melanomas that promote melanoma cell growth, survival and apoptotic resistance which contribute to the unresponsiveness of melanomas to traditional chemotherapeutic agents [@pone.0000594-Atkins1].

While gene signatures associated with aggressive melanomas provide insights into molecular pathways important for tumor progression, further analysis of these tumor cell lines in conjunction with expression profiles from primary human melanocytes using SAM analysis revealed a striking signature characterized exclusively by gene loss in melanomas and primarily by loss of cellular adhesion and melanocyte differentiation-associated genes ([Figures 2B, 2C](#pone-0000594-g002){ref-type="fig"}). We suggest that this melanoma-associated signature defines critical molecular mechanisms involved in melanocyte development and differentiation which distinguish these tumor cells from their primary cell of origin. In fact, the identification of several genes in this signature with established functional roles in melanocyte differentiation and melanin biosynthesis such as *CDH3, CDH1, c-KIT, PAX3, CITED1/MSG-1, TYR, MELANA, MC1R,* and *OCA2* [@pone.0000594-Nishimura1]--[@pone.0000594-Suzuki1], supports this notion. Moreover, this signature has identified two tumor suppressor genes, DPP4 and SYK, whose downregulation has previously been implicated in melanoma development [@pone.0000594-Houghton1]--[@pone.0000594-Muthusamy1].

Finally, evaluation of an invasion-specific signature for melanoma identified dominant gene activation by the transcription factor, NF-κB. Constitutive activation of NF-κB and an inflammatory response is an emerging hallmark of various tumor types [@pone.0000594-Karin1]. In addition, NF-κB has specifically been implicated in the development of invasive aggressive melanomas through autocrine and paracrine mechanisms (reviewed in [@pone.0000594-Ueda1]). Our melanoma invasion signature is associated with upregulation of critical NF-κB effectors including CXCL1, FMN2, MMP1, IL-8, IGFBP3 which have been implicated in the regulation of tumor cell proliferation, motility, migration, and/or invasion ([Figure 3D](#pone-0000594-g003){ref-type="fig"}). In addition, the putative NF-κB target gene GAGE7B which we identified in our melanoma invasion-specific signature, has been associated with apoptotic resistance and worse prognosis in other tumors [@pone.0000594-Cilensek1]. In addition, several of our invasion-specific signature genes are chemokines including CXCL1, CXCL2, and IL-8 which have been implicated in the promotion of tumor-associated angiogenesis, a critical feature of invasive tumors [@pone.0000594-Rofstad1].

In summary, our gene expression profiling studies of melanoma cell lines from varying stages of malignant progression and primary human melanocytes have identified several important melanoma signatures including: 1) Aggressive melanomas are characterized by upregulation of genes associated with cell cycle progression, DNA replication and repair and apoptotic resistance as well as loss of genes associated with apoptotic susceptibility, 2) Melanomas notably differ from their cell of origin, primary human melanocytes, due to a loss of cellular adhesion and differentiation-associated genes, and 3) Invasive melanomas are characterized by a signature indicative of global activation of NF-κB and downstream effector genes associated with tumor cell migration, invasion, chemotaxis, and proliferation. Since pathways associated with tumor progression may have clinical utility as prognostic tumor markers and therapeutic targets, we expect novel melanoma signature genes identified in this study will be further developed for such translational endpoints. Moreover, the important information regarding melanoma biology gleaned from these studies on renewable cell resources cannot be understated. A major roadblock to advances in melanoma therapy has been the relative paucity of informative tissue specimens available for analysis in profiling studies as well as the notoriously heterogeneous nature of this malignancy. The use of surrogate tissue resources including tumor cell lines for the early discovery phases in melanoma, as used in this study, will undoubtedly allow for the conservation of precious tissue specimens for use in more advanced validation studies. It is expected that the novel melanoma progression-associated genes identified in this study will provide new insights into the molecular defects associated with this malignancy and ultimately pave the way for the development of new melanoma biomarkers and novel targeted therapies.

Materials and Methods {#s4}
=====================

Cells {#s4a}
-----

Ten melanoma cell lines (WM35, SBC12, and WM1552C, WM902B, WM278, WM983A, and WM793, WM852, WM983B, 1205Lu) were obtained from M. Herlyn (The Wistar Institute, Philadelphia, PA). These cell lines were maintained in modified complete melanocyte growth medium (Cell Application Inc., San Diego, CA) which lacked 12-*O* -tetradecanoyl phorbol-13-acetate and was supplemented with 2 % fetal bovine serum. Normal human primary melanocytes were isolated from neonatal foreskins and grown in complete melanocyte growth medium (Cell Applications, Cat. No., 135--500). The complete melanocyte growth medium is consisted of the melanocyte basal medium (Cell Applications, Cat. No. 134-500) and growth supplement cocktails containing hydrocortisone (0.5 µg/ml), insulin (5 µg/ml), 12-O-tetradecanoylphorbol-13-acetate (10 ng/ml), bovine pituitary extract (21 µg/ml), bFGF (1 ng/ml), heparin (1 µg/ml), FBS (0.5 %), gentamycin sulfate (50 µg/ml), amphotericin B (5 ng/ml), and NaCl (45 mM).

Gene Expression Profiling {#s4b}
-------------------------

Total RNA was isolated from exponentially growing melanoma cell lines using RNeasy column purification per manufacturer\'s protocol (Qiagen). Two sets of short-term cultured (2 to 3 passage numbers) normal human melanocytes were prepared from neonatal foreskins. In order to minimize genetic variability melanocytes from 4--5 individuals were pooled for each culture. Total RNA from normal melanocytes was extracted and purified by a combination of phase extraction and chromatography using TRIzol reagent (Invitrogen Life Technologies Inc.) and RNeasy columns (Qiagen) in order to remove melanin. In brief, exponentially growing melanocytes were lysed with TRIzol reagent and lysate was incubated at 65°C for 2 minutes to inactivate melanin. Lysate was then subjected to phase extraction and RNeasy column purification. RNA quality checks, double strand complementary DNA synthesis, hybridization with Human Genome U133 Plus 2.0 Array Chips (Affymetrix Inc. Santa Clara, CA), and initial data extraction were performed at The Gene Array Core Facility in the Malaria Research Institute (JHMRI) at The Johns Hopkins Bloomberg School of Public Health (<http://malaria.jhsph.edu/jhmri/resources_education/gene_array_core>).

Data Extraction and Statistical Analysis {#s4c}
----------------------------------------

SAM [@pone.0000594-Tusher1], Gene Cluster 3.0 [@pone.0000594-deHoon1] and TreeView ([http://bonsai.ims.u-tokyo.ac.jp/∼mdehoon/software/cluster/index.html](http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/index.html)), Access, and Excel (Microsoft, Seattle, WA) programs were used. For all of the statistical analysis beyond the initial description of datasets, microarray data were normalized ([Dataset S1](#pone.0000594.s001){ref-type="supplementary-material"}) and a subset of the 12 microarray data (10 from melanoma cell lines and 2 from normal human melanocytes) was obtained by filtering to require each gene probe to have at least one observation in the expression intensity resulting in a 'present' call from all 12 samples. This produced a subset of data containing a total of 32,632 affymetrix gene probes ([Dataset S2](#pone.0000594.s002){ref-type="supplementary-material"}). This filtered subset of data was used for all of the additional analysis. *Cluster Analysis.* Unsupervised hierarchical clustering analysis was performed on the subset of data (without log transformation) with Gene Cluster 3.0 ([http://bonsai.ims.u-tokyo.ac.jp/∼mdehoon/software/cluster/index.html](http://bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster/index.html)) by using the correlation (uncentered) similarity metric and centeroid linkage clustering method. The resulting tree-images were visualized using Java TreeView. *Statistical Analysis of Microarray (SAM).* SAM was performed on the subset of array data without log transformation using SAM software package. Groups are defined based on the hierarchical clustering; for example, group 1  =  less-aggressive primary melanomas (RGP melanomas: WM35, Sbcl2, WM1552C and VGP melanomas: WM902B and WM278), and group 2  =  aggressive metastatic melanomas (Metastatic melanomas: WM852, WM983B, and 1205Lu; and VGP melanomas: WM983A and WM793) as seen [Figure 1](#pone-0000594-g001){ref-type="fig"}. Delta was chosen to limit the output gene list so that minimum predicted false-positives would be included. *Three-step Data Reduction Algorithm.* In order to identify melanoma invasion-specific gene signature, uniquely designed three-step data reduction algorithm was applied to the subset of expression data. First step is that the proveset should be called as 'present' in three samples out of four VGP melanoma cells and two samples out of three RGP melanoma cells. Second step is that the candidate proveset should be expressed five folds or more in VGP melanoma cell lines than RGP melanoma cell lines. The last step is that the gene probesets were retained only when the expression level is greater than three folds in VGP melanoma cell lines compared to that of primary human melanocytes. The last step is implemented because the candidate gene expression level should be higher if the gene products have certain degree of functional roles in the invasion processes of malignant melanoma. The probesets, those that pass through three-step filtration criteria are subjected to probeset to gene mapping using NetAffx, a web interface program from Affymetrix Inc. Gene annotation for the gene mane, gene symbol, and GO Biological Procession Analysis also performed by the NetAffx.

Quantitative Real-time PCR {#s4d}
--------------------------

cDNA was generated by using the SuperScript™ First-Strand Synthesis System for RT-PCR according to manufacturers instructions (Invitrogen, Carlsbad, CA). Quantitative real-time PCR was performed with an Applied Biosystems Prism 7900 HT Sequence Detection System using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). The thermal cycling conditions for quantitative real-time RT-PCR analysis to validate gene expression changes were as follows: hold for 10 minutes at 95°C, followed by three-step PCR for 40 cycles of 95°C for 15 seconds, 55°C to 60°C for 25 seconds, and 72°C for 30 seconds. Optimal annealing temperatures were predetermined to ensure single amplified product. All samples were performed in triplicate. Amplification data were analyzed with an Applied Biosystems Prism Sequencer Detection Software Version 2.3 (Applied Biosystems, Forster City, CA). Human *GAPDH* gene was used as endogenous control. To normalize the relative expression of the genes of interest to the *GAPDH* control, standard curves were prepared for each gene and *GAPDH* in each experiment.

Semi-quantitative Duplex PCR {#s4e}
----------------------------

Semi-quantitative duplex RT-PCR was performed by an MJ Research Programmable Thermal Controller (PTC-100, Inc., Watertown, MA) and the amplified products were separated on an agarose gel. Our duplex PCR utilized 20 bp oligonucleotides to amplify regions of 300--400 bp from the genes of interest. Intitial optimization experiments were conducted to establish the most favorable primer concentrations between the genes of interest and internal control GAPDH, yielding 0.8 µM and 0.04 µM, respectively. The PCR was carried out in a total volume of 25 µL, containing 2.5 µL of 10X PCR Buffer (containing 15 mM MgCl~2~), 0.2 mM dNTPs, and 0.3 ul AmpliTaq Gold DNA Polymerase (Applied Biosystems, Foster City, CA). Thirty to thirty-five amplification cycles were performed by an MJ Research Programmable Thermal Controller (PTC-100, Inc., Watertown, MA), using a denaturing temperature of 95°C for 25 seconds, an annealing temperature varying between 55°C−60°C (depending on gene) for 30 seconds, and primer extension at 72°C for 30 seconds. Each amplification experiment also included two negative PCR controls, a no-RNA control from reverse transcription procedures and a no-cDNA water control. Following amplification, 25 µL of the samples were separated via electrophoresis on a 3% agarose gel. The primer sequences were designed by using Primer3, primer analysis software (<http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi>), yielded only one amplified product and had the following sequences:[](#pone-0000594-t004){ref-type="table"}
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  -------- -------------------------------------
  MELK      Forward: 5′-TGGCTCTCTCCCAGTAGCAT-3′
            Reverse: 5′-TAGCACTGGCTTGTCCACAG-3′
  GINS4     Forward: 5′-CAGAGAGTTCATGGCGAACA-3′
            Reverse: 5′-CTCCCAAAGTGCTGGGATTA-3′
  NCAPG     Forward: 5′-TATTGGTGTGCCCTTTGTGA-3′
            Reverse: 5′-CAGGGATATTGGGATTGTGG-3′
  CDH3      Forward: 5′-ACGACACCCTCTTGGTGTTC-3′
            Reverse: 5′-GTCAAACTGCCCACATTCCT-3′
  KIT       Forward: 5′-TGACTTACGACAGGCTCGTG-3′
            Reverse: 5′-AAGGAGTGAACAGGGTGTGG-3′
  DPP4      Forward: 5′-CAAATTGAAGCAGCCAGACA-3′
            Reverse: 5′-CAGGGCTTTGGAGATCTGAG-3′
  SYR       Forward: 5′-GAAGCCATATCGAGGGATGA-3′
            Reverse: 5′-TGACAAGTTGTGGGCATGTT-3′
  CXCL1     Forward: 5′-TGTTTGAGCATCGCTTAGGA-3′
            Reverse: 5′-GATCTCATTGGCCATTTGCT-3′
  CXCL2     Forward: 5′-TTGCGCCTAATGTGTTTGAG-3′
            Reverse: 5′-ATACATTTCCCTGCCGTCAC-3′
  IL8       Forward: 5′-AGGGTTGCCAGATGCAATAC-3′
            Reverse: 5′-AGCAGACTAGGGTTGCCAGA-3′
  IGFBP3    Forward: 5′-GCTACAGCATGCAGAGCAAG-3′
            Reverse: 5′-AACATGTGGTGAGCATTCCA-3′
  GAPDH     Forward: 5′-GATCATCAGCAATGCCTCCT-3′
            Reverse: 5′-TTCAGCTCAGGGATGACCTT-3′
  -------- -------------------------------------

Immunofluorescence Labeling {#s4f}
---------------------------

RGP and VGP Cells were plated on glass slides and cultured in melanocyte growth media overnight without any stimulation. Cells were fixed at room temperature for 15 minutes using 3.5% para-formaldehyde solution. Cells were washed briefly with PBS and then permeabilized with either 0.5% Triton X-100 for 10 minutes or −20°C cooled methanol for 15 minutes. Slides were blocked with 16% normal goat serum (Santa Cruz Biotech., Santa Cruz, CA) for 1 hour and then incubated with rabbit polyclonal IgG p65 antibody (Santa Cruz Biotech., Santa Cruz, CA) at 1:100 dilution. Subsequent to overnight incubation at 4°C, the slides were washed with PBS and incubated with goat anti-rabbit IgG-Alexa 594 (Molecular Probes Eugene, OR) at 1:200 dilution at room temperature for 1 hour. Stained slides were washed with PBS and viewed under a fluorescence microscope (Eclipse TS100, Nikon, Tokyo, Japan).

Gene Transcription Promoter Analysis {#s4g}
------------------------------------

Transcription factor binding *cis* element sequence profiling in the selected gene promoter was performed by using a web tool known as TESS (Transcription Element Search System, <http://www.cbil.upenn.edu/tess>). Each genes promoter sequences from the transcription start site up to 2.0 kb of upstream of the genes were subjected to the TESS and screened by TRANSFAC database to identify matched consensus sequences of known DNA binding transcription factors.
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======================

###### 

A combined and normalized raw dataset from the 12 sets of microarray data (two sets of primary human melanocytes and ten melanoma cell lines).

(18.02 MB DOC)

###### 

Click here for additional data file.

###### 

A subset of the 12 microarray data (10 from melanoma cell lines and 2 from human primary melanocytes) was obtained by filtering to require each Affymetrix probe to have at least one observation in the expression intensity resulting in a present call from all 12 samples.

(4.50 MB DOC)

###### 

Click here for additional data file.

###### 

Results of SAM analysis between Group 1 and Group 2 melanoma cells. The results include the SAM Output showing the list of Affymetrix probesets and associated gene symbols that are differentially expressed in the two groups of melanoma cell lines.

(3.20 MB DOC)

###### 

Click here for additional data file.

###### 

Results of SAM analysis between HPMs and Group 2 melanoma cells. The results include the SAM Output showing the list of Affymetrix probesets and associated gene symbols that are downregulated in Group 2 melanoma cell lines.

(3.05 MB DOC)

###### 

Click here for additional data file.

We thank M. Herlyn (Wistar Institute) for generously providing melanoma cell lines used in these studies. We thank G. Parmigiani (Johns Hopkins University School of Medicine) for his statistical support and members of the Alani Lab for their careful review of this manuscript and helpful comments.

**Competing Interests:**The authors have declared that no competing interests exist.

**Funding:**National Institutes of Health Grants CA107017 (RA) and CA113779 (BR), American Skin Association (R.A., A.D.), Flight Attendant Medical Research Institute (R.A.), The Murren Family Foundation (R.A.), and The Henry and Elaine Kaufman Foundation (R.A.).

[^1]: Conceived and designed the experiments: RA BR. Performed the experiments: BR DK AD. Analyzed the data: RA BR DK AD. Contributed reagents/materials/analysis tools: BR. Wrote the paper: RA BR.
